-
KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment
•
Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 product KPC-149, which is intended for the treatment of familial Mediterranean fever (FMF). FMF is an autosomal recessive autoimmune disease associated with mutations in…
-
KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine
•
Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received Prequalification (PQ) status from the World Health Organization (WHO). This critical milestone allows the anti-malaria drug to be included in the procurement scope of international organizations and public health institutions, enhancing its accessibility in malaria-affected…
